Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 4Recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Other solid neoplasm 1

Conditions

Breast Neoplasms 1324Neoplasms 982Carcinoma, Non-Small-Cell Lung 860Prostatic Neoplasms 724Colorectal Neoplasms 666Lung Neoplasms 551Leukemia, Myeloid, Acute 475Neoplasm Metastasis 434Pancreatic Neoplasms 419Carcinoma, Hepatocellular 407Multiple Myeloma 396Ovarian Neoplasms 392Stomach Neoplasms 379Recurrence 364Squamous Cell Carcinoma of Head and Neck 325Melanoma 294Brain Neoplasms 287Uterine Cervical Neoplasms 283Triple Negative Breast Neoplasms 271Glioblastoma 264Head and Neck Neoplasms 263Precursor Cell Lymphoblastic Leukemia-Lymphoma 254Endometrial Neoplasms 234Lymphoma 228Rectal Neoplasms 222Esophageal Neoplasms 222Sarcoma 213Carcinoma, Renal Cell 203Colonic Neoplasms 194Lymphoma, Non-Hodgkin 191

Interventions

Paclitaxel 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Interventional × Platinum-resistant Recurrent Ovarian Cancer × Clear all
NCT06434610 2026-05-05

A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Shanghai Jiaolian Drug Research and Development Co., Ltd

Phase 2 Recruiting
90 enrolled
Gynecologic

Platinum-resistant Recurrent Ovarian Cancer

NCT06687070 2025-02-26

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST

Ascentage Pharma Group Inc.

Phase 1 Recruiting
50 enrolled
GynecologicOther solid neoplasm

Platinum-resistant Recurrent Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡